Trial Profile
An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Epoetin delta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Shire
- 05 Oct 2021 Trial has been completed in franc (global end date :2008-07-31)as per European Clinical Trials Database record
- 06 Jun 2014 New trial record